Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2023 Filed Feb 15, 2023 21:45 UTC |
Siegel JolieChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001662579-23-000038 · wf-form4_167649753180992.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:45 UTC |
Siegel JolieChief Legal Officer
|
GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000038 · wf-form4_167649753180992.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,097 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:45 UTC |
Schick KellyChief People Officer
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001662579-23-000036 · wf-form4_167649749262715.xml · derivative · entry 2 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 13, 2023. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:45 UTC |
Schick KellyChief People Officer
|
GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000036 · wf-form4_167649749262715.xml · nonDerivative · entry 1 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,097 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 13, 2024. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 21:27 UTC |
Koppikar UtpalDirector
|
PurchaseCommon Stock | 5,667 | $5.60 | $31,735.20 |
DisclosureSEC source: 0001662579-23-000027 · wf-form4_167606442384071.xml · nonDerivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,667 Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:10 UTC |
Boyle Scott NChief Business Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000022 · wf-form4_167528579820409.xml · derivative · entry 3 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:10 UTC |
Boyle Scott NChief Business Officer
|
Tax withholdingCommon Stock | 1,222 | $7.78 | $9,507.16 |
DisclosureSEC source: 0001662579-23-000022 · wf-form4_167528579820409.xml · nonDerivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,176 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 16:10 UTC |
Boyle Scott NChief Business Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000022 · wf-form4_167528579820409.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:10 UTC |
White LaurenChief Financial Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000023 · wf-form4_167528583720918.xml · derivative · entry 3 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:10 UTC |
White LaurenChief Financial Officer
|
Tax withholdingCommon Stock | 1,301 | $7.78 | $10,121.78 |
DisclosureSEC source: 0001662579-23-000023 · wf-form4_167528583720918.xml · nonDerivative · entry 2 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,097 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:10 UTC |
White LaurenChief Financial Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000023 · wf-form4_167528583720918.xml · nonDerivative · entry 1 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Hirsch AndrewDirector · President & CEO
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000021 · wf-form4_167528577737212.xml · derivative · entry 3 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 12,500 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Hirsch AndrewDirector · President & CEO
|
Tax withholdingCommon Stock | 4,319 | $7.78 | $33,601.82 |
DisclosureSEC source: 0001662579-23-000021 · wf-form4_167528577737212.xml · nonDerivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,006 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Hirsch AndrewDirector · President & CEO
|
Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000021 · wf-form4_167528577737212.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:11 UTC |
Crystal AdamChief Medical Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000024 · wf-form4_167528585798757.xml · derivative · entry 3 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:11 UTC |
Crystal AdamChief Medical Officer
|
Tax withholdingCommon Stock | 1,301 | $7.78 | $10,121.78 |
DisclosureSEC source: 0001662579-23-000024 · wf-form4_167528585798757.xml · nonDerivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,097 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:11 UTC |
Crystal AdamChief Medical Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000024 · wf-form4_167528585798757.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Schick KellyChief People Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000020 · wf-form4_167528575707675.xml · derivative · entry 3 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Schick KellyChief People Officer
|
Tax withholdingCommon Stock | 1,301 | $7.78 | $10,121.78 |
DisclosureSEC source: 0001662579-23-000020 · wf-form4_167528575707675.xml · nonDerivative · entry 2 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,097 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Schick KellyChief People Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000020 · wf-form4_167528575707675.xml · nonDerivative · entry 1 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Siegel JolieChief Legal Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000019 · wf-form4_167528573105921.xml · derivative · entry 3 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Siegel JolieChief Legal Officer
|
Tax withholdingCommon Stock | 1,301 | $7.78 | $10,121.78 |
DisclosureSEC source: 0001662579-23-000019 · wf-form4_167528573105921.xml · nonDerivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,097 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:09 UTC |
Siegel JolieChief Legal Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000019 · wf-form4_167528573105921.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:08 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001662579-23-000018 · wf-form4_167528571311726.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:08 UTC |
Fisher StewartChief Scientific Officer
|
Tax withholdingCommon Stock | 1,301 | $7.78 | $10,121.78 |
DisclosureSEC source: 0001662579-23-000018 · wf-form4_167528571311726.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,487 F2 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 21:08 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001662579-23-000018 · wf-form4_167528571311726.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:55 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 444 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001662579-23-000008 · wf-form4_167304210044893.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 890 Underlying: Common Stock · 444 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:55 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 268 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001662579-23-000008 · wf-form4_167304210044893.xml · derivative · entry 8 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067 Underlying: Common Stock · 268 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 12.5% of the shares underlying this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:55 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionCommon Stock | 444 | $4.98 | $2,211.12 |
DisclosureSEC source: 0001662579-23-000008 · wf-form4_167304210044893.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2023 Filed Jan 6, 2023 21:55 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionCommon Stock | 268 | $2.11 | $565.48 |
DisclosureSEC source: 0001662579-23-000008 · wf-form4_167304210044893.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 16:16 UTC |
Dubin GlennDirector
|
GrantCommon Stock | 1,725 | $6.38 | $11,005.50 |
DisclosureSEC source: 0001662579-23-000004 · wf-form4_167286693048091.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,235 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:17 UTC |
Anderson Kenneth CarlDirector
|
GrantCommon Stock | 1,568 | $6.38 | $10,003.84 |
DisclosureSEC source: 0001662579-23-000006 · wf-form4_167286703601250.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,416 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 3, 2023. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 21:17 UTC |
GROGAN DONNA ROYDirector
|
GrantCommon Stock | 1,763 | $6.38 | $11,247.94 |
DisclosureSEC source: 0001662579-23-000005 · wf-form4_167286698318570.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,582 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on January 3, 2023. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 18:06 UTC |
Dubin GlennDirector
|
GrantCommon Stock | 1,265 | $8.69 | $10,992.85 |
DisclosureSEC source: 0001662579-22-000005 · wf-form4_166492113147782.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,510 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 3, 2022. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 445 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · derivative · entry 10 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334 Underlying: Common Stock · 445 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 267 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,335 Underlying: Common Stock · 267 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 12.5% of the shares underlying this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC |
Anderson Kenneth CarlDirector
|
GrantCommon Stock | 1,150 | $8.69 | $9,993.50 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · nonDerivative · entry 3 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,848 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 3, 2022. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionCommon Stock | 445 | $4.98 | $2,216.10 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:05 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionCommon Stock | 267 | $2.11 | $563.37 |
DisclosureSEC source: 0001662579-22-000004 · wf-form4_166492110095346.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 4, 2022 22:06 UTC |
GROGAN DONNA ROYDirector
|
GrantCommon Stock | 819 | $8.69 | $7,117.11 |
DisclosureSEC source: 0001662579-22-000006 · wf-form4_166492116846862.xml · nonDerivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on October 3, 2022. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:24 UTC |
GROGAN DONNA ROYDirector
|
GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $9.64 | $0.00 |
DisclosureSEC source: 0001209191-22-043870 · doc4.xml · derivative · entry 1 GROGAN DONNA ROY · CIK 0001788455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2032-07-28 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on July 29, 2023, with the remainder vesting in eight equal quarterly installments thereafter. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:23 UTC |
Bessen LauraDirector
|
GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $9.64 | $0.00 |
DisclosureSEC source: 0001209191-22-043869 · doc4.xml · derivative · entry 1 Bessen Laura · CIK 0001926815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2032-07-28 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on July 29, 2023, with the remainder vesting in eight equal quarterly installments thereafter. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 21:18 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 889 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-22-042457 · doc4.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,779 Underlying: Common Stock · 889 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 21:18 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 535 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-22-042457 · doc4.xml · derivative · entry 8 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,602 Underlying: Common Stock · 535 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 12.5% of the shares underlying this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 21:18 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionCommon Stock | 889 | $4.98 | $4,427.22 |
DisclosureSEC source: 0001209191-22-042457 · doc4.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2022 Filed Jul 18, 2022 21:18 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionCommon Stock | 535 | $2.11 | $1,128.85 |
DisclosureSEC source: 0001209191-22-042457 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 16:12 UTC |
Dubin GlennDirector
|
GrantCommon Stock | 1,372 | $8.03 | $11,017.16 |
DisclosureSEC source: 0001209191-22-040603 · doc4.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,245 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2022. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:11 UTC |
Anderson Kenneth CarlDirector
|
GrantCommon Stock | 1,246 | $8.03 | $10,005.38 |
DisclosureSEC source: 0001209191-22-040597 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,562 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on July 1, 2022. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:15 UTC |
COHEN MARC ADirector
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038863 · doc4.xml · derivative · entry 1 COHEN MARC A · CIK 0001132945 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:15 UTC |
Salter MalcolmDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038862 · doc4.xml · derivative · entry 1 Salter Malcolm · CIK 0001825124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.